A Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis
Latest Information Update: 24 Aug 2022
At a glance
- Drugs TLX 66 (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- Acronyms TRALA
- 31 May 2021 New trial record
- 24 May 2021 According to a Telix Pharmaceuticals Limited media release, Dr. Kim Orchard, Consultant Hematologist at University Hospital Southampton is a principal investigator of the study.
- 24 May 2021 Results presented in a Telix Pharmaceuticals media release.